Orion
49.08
EUR
-0.53 %
13,957 following
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
-0.53%
-11.66%
+0.1%
+14.73%
+3.11%
+50.28%
+14.54%
+12.39%
+337.04%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Read moreMarket cap
6.93B EUR
Turnover
8.05M EUR
P/E (adj.) (25e)
21
EV/EBIT (adj.) (25e)
16.48
P/B (25e)
6.26
EV/S (25e)
4.25
Dividend yield-% (25e)
3.46 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
23.4
2025
Interim report Q1'25
18.7
2025
Interim report Q2'25
15.10
2025
Half year dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orion Corporation: Organising meeting of the Board of Directors
Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025
